Tag: bevacizumab
1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients with advanced unresectable hepatocellular carcinoma.
2. Patients treated with the combinatorial treatment of atezolizumab and bevacizumab were shown to experience serious toxic side effects.
Evidence Rating Level: 1 (Excellent)
Hepatocellular carcinoma is a...
1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients with advanced unresectable hepatocellular carcinoma.
2. Patients treated with the combinatorial treatment of atezolizumab and bevacizumab were shown to experience serious toxic side effects.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Hepatocellular...
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive disease.
Evidence Rating Level: 2 (Good)
Although previous investigations have indicated that the immune system plays an important role in ovarian cancer control, results from trials thus far on single-agent immune...
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive disease.
Evidence Rating Level: 2 (Good)
Although previous investigations have indicated that the immune system plays an important role in ovarian cancer control, results from trials thus far on single-agent immune...
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial
1. Adjuvant FOLFOX improves disease-free survival in patients with pathologic Stage II or III rectal cancer after upfront surgery and preoperative chemoradiotherapy, but is associated with a higher rate of adverse events.
Evidence...
Screening for breech presentation using universal late-pregnancy ultrasonography: A prospective cohort study and cost effectiveness analysis
Fetal presentation has long been determined by way of clinical examination only, despite the relative ease with which breech presentation can be identified through ultrasound screening. As such, many women continue to present in...
1. In a phase III trial of over 370 patients with advanced breast cancer, the addition of anti-vascular endothelial growth factor (VEGF) agent bevacizumab to endocrine therapy (ET) for breast cancer did not significantly increase progression free or overall survival compared to ET alone.
Evidence Rating Level: 1 (Excellent)
Study Rundown:...
1. Tuberculosis (TB) granulomas exhibited similar properties to solid cancerous tumors, characterized as dense tissue masses with abnormal blood vessel distribution, which is thought to result in reduced penetration of TB drugs into the granuloma.
2. In a rabbit model of TB granulomas, treatment with the angiogenesis inhibitor bevacizumab, shown...
1. There was no overall increase in systemic cardiovascular events with the use of antibodies to vascular endothelial growth factor (anti-VEGF) therapies in the eye (Avastin or Lucentis).
2. Subgroup analysis indicated a significant increase in clot formation with Avastin use and an increase in bleeding with age-related macular degeneration...
Image: PD
1. Combining bevacizumab with standard chemotherapy improved progression free survival and objective response rate in platinum-resistant ovarian cancer.
2. Adding bevacizumab did not significantly affect overall survival.
Evidence rating level: 1 (Excellent)
Study Rundown: Platinum-resistant recurrent ovarian cancer has an extremely poor prognosis, and is generally treated with single-agent chemotherapy with...